Cowen Downgrades Celldex Therapeutics (CLDX) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
UPDATE: Cantor Fitzgerald Downgrades Celldex Therapeutics (CLDX) to Neutral, 'Glemba in Rear View Mirror'
April 17, 2018 4:06 AM EDT(Updated - April 17, 2018 6:45 AM EDT)
(updated to add analyst comment)
Cantor Fitzgerald downgraded Celldex Therapeutics (NASDAQ: CLDX) from Overweight to Neutral with a price target of $3.00 (from $9.00).
Analyst Mara Goldstein comments "We had ascribed $6/share in value to... More
Celldex Therapeutics (CLDX) PT Lowered to $1 at Jefferies; 'METRIC PIII Trial Fails'
April 17, 2018 3:07 AM EDTJefferies lowered its price target on Celldex Therapeutics (NASDAQ: CLDX) to $1.00 (from $3.00) while maintaining a Hold rating.
... MoreCelldex Therapeutics (CLDX) PT Lowered to $2.50 at H.C. Wainwright
April 16, 2018 10:54 AM EDTH.C. Wainwright lowered its price target on Celldex Therapeutics (NASDAQ: CLDX) to $2.50 (from $10.00) while maintaining a Buy rating.
Analyst Joseph Pantginis commented, "This morning, Celldex announced that the Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic... More
Pre-Open Stock Movers 04/16: (ERI) (ALKS) (DVAX) Higher; (CLDX) (ALGT) (NLNK) Lower (more...)
April 16, 2018 9:23 AM EDTCelldex (NASDAQ: CLDX) 49% LOWER; announcing its Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint.
Eldorado Resorts, Inc. (NASDAQ: ERI) 14.8% HIGHER; entered into a definitive agreement to acquire Tropicana Entertainment Inc. (OTCQB: TPCA) in a cash transaction that is valued at $1.85 billion. The definitive agreement provides that Gaming and Leisure Properties (NASDAQ:... More
Celldex (CLDX) Set to Open Lower By 49% After METRIC Study Fails
April 16, 2018 8:24 AM EDTCelldex (NASDAQ: CLDX) was set to open lower by 49% Monday morning after announcing its Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint.
... MoreCelldex (CLDX) Announces Phase 2B METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint
April 16, 2018 7:04 AM EDTCelldex Therapeutics, Inc. (NASDAQ: CLDX) today reported that the Companys randomized, Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda® (capecitabine) in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint, progression-free survival (PFS) as assessed by an independent, central reading of patient scans (Hazard ratio = 0.95; median PFS: glembatumumab vedotin 2.9 months vs. Xeloda 2.8 months; p=0.76). There was no significant advantage for glembatumumab vedotin in key secondary endpoints, including overall response rate, duration of response and overall survival. The glembatumumab vedotin safety profile was consistent with prior... More
